Response gene to complement-32 enhances metastatic phenotype by mediating transforming growth factor beta-induced epithelial-mesenchymal transition in human pancreatic cancer cell line BxPC-3

Journal of Experimental and Clinical Cancer Research

Volumn 31, Issue 1, 2012, Pages

  Zhu, Liang ^a,b   Qin, Hua ^a   Li, Pei Yuan ^a   Xu, Sheng Nan ^a   Pang, Hui Fang ^a   Zhao, Hui Zhen ^a   Li, De Min ^a   Zhao, Qiu ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b NANCHANG UNIVERSITY   (China)

Author keywords

Epithelial mesenchymal transition; Migration; Pancreatic cancer; Response gene to complement 32; Transforming growth factor ? ?

Indexed keywords

COMPLEMENT; RESPONSE GENE TO COMPLEMENT 32; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UVOMORULIN; CADHERIN; CELL CYCLE PROTEIN; MUSCLE PROTEIN; NERVE PROTEIN; RGC32 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER STAGING; CELL MIGRATION; CHRONIC PANCREATITIS; CLINICAL ARTICLE; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; GENETIC COMPLEMENTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPH NODE METASTASIS; MALE; NUCLEOTIDE SEQUENCE; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; CELL MOTION; DRUG EFFECT; GENE EXPRESSION; GENETICS; METASTASIS; PANCREAS TUMOR; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

CADHERINS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMANS; MUSCLE PROTEINS; NEOPLASM METASTASIS; NERVE TISSUE PROTEINS; PANCREATIC NEOPLASMS; PHENOTYPE; RNA INTERFERENCE; TRANSFORMING GROWTH FACTOR BETA;

EID: 84858967143     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-31-29     Document Type: Article

References (32)

1. Advanced pancreatic carcinoma: current treatment and future challenges. Stathis A, Moore MJ, Nat Rev Clin Oncol 2010 7 163 172 10.1038/nrclinonc.2009. 236 20101258
2. Pancreatic cancer. Hidalgo M, N Engl J Med 2010 362 1605 1617 10.1056/NEJMra0901557 20427809
3. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Polyak K, Weinberg RA, Nat Rev Cancer 2009 9 265 273 10.1038/nrc2620 19262571
4. Epithelial-mesenchymal transitions in development and disease. Thiery JP, Acloque H, Huang RY, Nieto MA, Cell 2009 139 871 890 10.1016/j.cell.2009.11.007 19945376
5. Basics of TGF-beta and pancreatic cancer. Truty MJ, Urrutia R, Pancreatology 2007 7 423 435 10.1159/000108959 17898532 (Pubitemid 47587621)
6. Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Ellenrieder V, Hendler SF, Boeck W, Seufferlein T, Menke A, Ruhland C, Adler G, Gress TM, Cancer Res 2001 61 4222 4228 11358848 (Pubitemid 32720992)
7. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Bardeesy N, Cheng KH, Berger JH, Chu GC, Pahler J, Olson P, Hezel AF, Horner J, Lauwers GY, Hanahan D, DePinho RA, Genes Dev 2006 20 3130 3146 10.1101/gad.1478706 17114584 (Pubitemid 44790628)
8. Smad4 dependency defines two classes of transforming growth factor beta (TGF-{beta}) target genes and distinguishes TGF-{beta}-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses. Levy L, Hill CS, Mol Cell Biol 2005 25 8108 8125 10.1128/MCB.25.18. 8108-8125.2005 16135802 (Pubitemid 41263004)
9. TGFbeta-induced downregulation of E-cadherin-based cell-cell adhesion depends on PI3-kinase and PTEN. Vogelmann R, Nguyen-Tat MD, Giehl K, Adler G, Wedlich D, Menke A, J Cell Sci 2005 118 4901 4912 10.1242/jcs.02594 16219695 (Pubitemid 41646396)
10. Molecular cloning and characterization of RGC-32, a novel gene induced by complement activation in oligodendrocytes. Badea TC, Niculescu FI, Soane L, Shin ML, Rus H, J Biol Chem 1998 273 26977 26981 10.1074/jbc.273.41.26977 9756947 (Pubitemid 28471720)
11. RGC-32 increases p34CDC2 kinase activity and entry of aortic smooth muscle cells into S-phase. Badea T, Niculescu F, Soane L, Fosbrink M, Sorana H, Rus V, Shin ML, Rus H, J Biol Chem 2002 277 502 508 11687586 (Pubitemid 34952085)
12. Response gene to complement 32, a novel regulator for transforming growth factor-beta-induced smooth muscle differentiation of neural crest cells. Li F, Luo Z, Huang W, Lu Q, Wilcox CS, Jose PA, Chen S, J Biol Chem 2007 282 10133 10137 10.1074/jbc.C600225200 17327222 (Pubitemid 47093391)
13. Overexpression of RGC-32 in colon cancer and other tumors. Fosbrink M, Cudrici C, Niculescu F, Badea TC, David S, Shamsuddin A, Shin ML, Rus H, Exp Mol Pathol 2005 78 116 122 10.1016/j.yexmp.2004.11.001 15713436 (Pubitemid 40248792)
14. RGC32, a novel p53-inducible gene, is located on centrosomes during mitosis and results in G2/M arrest. Saigusa K, Imoto I, Tanikawa C, Aoyagi M, Ohno K, Nakamura Y, Inazawa J, Oncogene 2007 26 1110 1121 10.1038/sj.onc.1210148 17146433
15. A multigenic program mediating breast cancer metastasis to bone. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón-Cardo C, Guise TA, Massagué J, Cancer Cell 2003 3 537 549 10.1016/S1535-6108(03)00132-6 12842083 (Pubitemid 36808649)
16. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, Liang W, Michalopoulos G, Becich M, Monzon FA, BMC Cancer 2007 7 64 10.1186/1471-2407-7-64 17430594 (Pubitemid 47161402)
17. AJCC cancer staging manual. New York: Springer, Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, 7 2010
18. Epigenetic modifications induced by RGC-32 in colon cancer. Vlaicu SI, Tegla CA, Cudrici CD, Fosbrink M, Nguyen V, Azimzadeh P, Rus V, Chen H, Mircea PA, Shamsuddin A, Rus H, Exp Mol Pathol 2010 88 67 76 10.1016/j.yexmp.2009.10. 010 19883641
19. Abnormal immunoreactivity of the E-cadherin-catenin complex in gastric carcinoma: relationship with patient survival. Jawhari A, Jordan S, Poole S, Browne P, Pignatelli M, Farthing MJ, Gastroenterology 1997 112 46 54 10.1016/S0016-5085(97)70218-X 8978342 (Pubitemid 27008985)
20. Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling. Wang Y, Zhao Q, Ma S, Yang F, Gong Y, Ke C, IUBMB Life 2007 59 717 721 10.1080/15216540701646484 17968710 (Pubitemid 350035585)
21. Epithelial-mesenchymal transitions in tumour progression. Thiery JP, Nat Rev Cancer 2002 2 442 454 10.1038/nrc822 12189386
22. Epithelial-to-mesenchymal transition in pancreatic adenocarcinoma. Cano CE, Motoo Y, Iovanna JL, Scientific World Journal 2010 10 1947 1957 20890584
23. Controlling TGF-beta signaling. Massague J, Chen YG, Genes Dev 2000 14 627 644 10733523
24. The Smad pathway. Wrana JL, Attisano L, Cytokine Growth Factor Rev 2000 11 5 13 10.1016/S1359-6101(99)00024-6 10708948 (Pubitemid 30169721)
25. Mechanisms of the epithelial-mesenchymal transition by TGF-beta. Wendt MK, Allington TM, Schiemann WP, Future Oncol 2009 5 1145 1168 10.2217/fon.09.90 19852727
26. Phenotype and genotype of pancreatic cancer cell lines. Deer EL, González-Hernández J, Coursen JD, Shea JE, Ngatia J, Scaife CL, Firpo MA, Mulvihill SJ, Pancreas 2010 39 425 435 10.1097/MPA.0b013e3181c15963 20418756
27. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Wilentz RE, Iacobuzio-Donahue CA, Argani P, McCarthy DM, Parsons JL, Yeo CJ, Kern SE, Hruban RH, Cancer Res 2000 60 2002 2006 10766191 (Pubitemid 30207663)
28. RGC-32 mediates transforming growth factor-beta- induced epithelial-mesenchymal transition in human renal proximal tubular cells. Huang WY, Li ZG, Rus H, Wang X, Jose PA, Chen SY, J Biol Chem 2009 284 9426 9432 10.1074/jbc.M900039200 19158077
29. Re-solving the cadherin- Catenin-Actin Conundrum. Weis WI, Nelson WJ, J Biol Chem 2006 281 35593 35597 10.1074/jbc.R600027200 17005550 (Pubitemid 46043241)
30. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. von Burstin J, Eser S, Paul MC, Seidler B, Brandl M, Messer M, von Werder A, Schmidt A, Mages J, Pagel P, Schnieke A, Schmid RM, Schneider G, Saur D, Gastroenterology 2009 137 361 371 10.1053/j.gastro.2009.04.004 19362090
31. Expression of the E-cadherin-catenin complex in patients with pancreatic ductal adenocarcinoma. Pryczynicz A, Guziska-Ustymowicz K, Kemona A, Czyzewska J, Folia Histochem Cytobiol 2010 48 128 133 10.2478/v10042-008-0089-1 20529828
32. Abnormal expression of E-cadherin and beta-catenin may be a molecular marker of submucosal invasion and lymph node metastasis in early gastric cancer. Tanaka M, Kitajima Y, Edakuni G, Sato S, Miyazaki K, Br J Surg 2002 89 236 244 11856141 (Pubitemid 34124250)